Zydus Lifesciences, an Ahmedabad-based pharmaceutical company, has entered into a definitive agreement to acquire Assertio Holdings, a US-based pharma firm, for $166.40 million. The acquisition, executed through Zydus Worldwide DMCC, a subsidiary of Zydus, will see Assertio's shares purchased at $23.50 per share in cash. This strategic move is set to bolster Zydus's specialty oncology presence in the US, leveraging Assertio's established commercial platform and relationships in oncology supportive care. Sharvil P Patel, managing director of Zydus Lifesciences, emphasized that this acquisition aligns with the company's long-term strategy to create differentiated specialty businesses globally. Assertio's portfolio includes Rolvedon, an approved biologic for preventing febrile neutropenia in adult cancer patients undergoing chemotherapy, which further enhances Zydus's offerings in the oncology market.